» Articles » PMID: 23844915

Breast Cancer As a Systemic Disease: a View of Metastasis

Overview
Journal J Intern Med
Specialty General Medicine
Date 2013 Jul 13
PMID 23844915
Citations 331
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is now the most frequently diagnosed cancer and leading cause of cancer death in women worldwide. Strategies targeting the primary tumour have markedly improved, but systemic treatments to prevent metastasis are less effective; metastatic disease remains the underlying cause of death in the majority of patients with breast cancer who succumb to their disease. The long latency period between initial treatment and eventual recurrence in some patients suggests that a tumour may both alter and respond to the host systemic environment to facilitate and sustain disease progression. Results from studies in animal models suggest that specific subtypes of breast cancer may direct metastasis through recruitment and activation of haematopoietic cells. In this review, we focus on data implicating breast cancer as a systemic disease.

Citing Articles

ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.

Bharde A, Nadagouda S, Dongare M, Hariramani K, Basavalingegowda M, Haldar S J Liq Biopsy. 2025; 7:100284.

PMID: 40027235 PMC: 11863978. DOI: 10.1016/j.jlb.2024.100284.


Identification of Molecular Subtypes and Prognostic Features of Breast Cancer Based on TGF-β Signaling-related Genes.

Qu J, Wang M, Gao Y, Zhang H Cancer Inform. 2025; 24:11769351251316398.

PMID: 39902175 PMC: 11789128. DOI: 10.1177/11769351251316398.


Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.

Lee S, Ricci B, Tran J, Eul E, Ye J, Ren Q Nat Commun. 2025; 16(1):1183.

PMID: 39885132 PMC: 11782527. DOI: 10.1038/s41467-025-56420-w.


CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 - metastatic breast cancer.

Dent S, Guha A, Moore H, Makari D, McCaleb R, Arias I Cardiooncology. 2025; 11(1):7.

PMID: 39871392 PMC: 11771012. DOI: 10.1186/s40959-025-00305-w.


Covert Breast Cancer Metastasis to the Gastrointestinal Tract: Is Extra Vigilance Needed?.

Wehbe S, Firkins S, Sweeney J, Moore H, Rouphael C ACG Case Rep J. 2025; 12(1):e01582.

PMID: 39829946 PMC: 11741208. DOI: 10.14309/crj.0000000000001582.


References
1.
de Albuquerque A, Kubisch I, Ernst D, Breier G, Stamminger G, Fersis N . Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. Clin Lab. 2012; 58(5-6):373-84. View

2.
Kalluri R, Zeisberg M . Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. DOI: 10.1038/nrc1877. View

3.
Pugh C, Gleadle J, Maxwell P . Hypoxia and oxidative stress in breast cancer. Hypoxia signalling pathways. Breast Cancer Res. 2001; 3(5):313-7. PMC: 138694. DOI: 10.1186/bcr313. View

4.
Munzone E, Botteri E, Sandri M, Esposito A, Adamoli L, Zorzino L . Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer. 2012; 12(5):340-6. DOI: 10.1016/j.clbc.2012.07.001. View

5.
Nguyen D, Bos P, Massague J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9(4):274-84. DOI: 10.1038/nrc2622. View